New nasal spray could offer quick migraine relief for those on preventives

NCT ID NCT06401642

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests zavegepant (Zavzpret), a nasal spray already approved for migraines, in 200 adults who also take CGRP-targeting preventive medications. Researchers want to see if it provides headache relief within 2 to 4 hours and improves daily function. The goal is to find a safe, effective rescue treatment for people already managing migraines with preventives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

zavegepant (Zavzpret) nasal spray

What this could lead to

If it works, this could give people on migraine preventives a fast-acting option to stop migraine attacks when they occur.

What could go wrong

This is a small, early-phase study (200 people) and results may not apply to everyone. Side effects are possible, and the drug may not work better than existing options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Phoenix, Arizona, 85254, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact